Nitric oxide and prostacyclin as test agents of vasoreactivity in severe precapillary pulmonary hypertension: Predictive ability and consequences on haemodynamics and gas exchange

Thorax

Volumn 52, Issue 4, 1997, Pages 369-372

  Jolliet, Philippe ^a,b   Bulpa, Pierre ^a   Thorens, Jean Benoît ^a   Ritz, Marc ^a   Chevrolet, Jean Claude ^a  

^a UNIVERSITY HOSPITAL   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Calcium channel blockers; Nitric oxide; Prostacyclin; Pulmonary hypertension; Vasodilators

Indexed keywords

CALCIUM ANTAGONIST; NIFEDIPINE; NITRIC OXIDE; PROSTACYCLIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; GAS EXCHANGE; HEMODYNAMICS; HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; VASCULAR RESISTANCE; VASODILATATION;

EID: 0030955773     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.52.4.369     Document Type: Article

References (14)

1. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81.
2. Partanen J, Nieminen M, Luomanmäki K. Death in a patient with primary pulmonary hypertension after 20 mg of nifedipine. N Engl J Med 1993;329:812.
3. Palevsky HI, Long W, Crow J, Fishman AP. Prostacyclin and acetylcholine as screening agents for acute pulmonary vasodilator responsiveness in primary pulmonary hypertension. Circulation 1990;82:2018-26.
4. Sitbon O, Brenot F, Denjean A, Bergeron A, Parent F, Azarian R, et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. Am J Respir Crit Care Med 1995;151:384-9.
5. Cockrill BA, Kackmarek R, Thompson BT, Zapol WA, Semigran MJ. Response to inhaled nitric oxide identities a subset of patients with pulmonary hypertension likely to respond to high dose calcium channel antagonists. Am J Respir Crit Care Med 1995;151:A728.
6. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987;107:216-23.
7. Chevrolet JC, Schmid F. "Spontaneous" variability of pulmonary haemodynamics during vasodilator tests in pulmonary precapillary hypertension. Eur J Intern Med 1992; 3:305-17.
8. Jolliet P, Thorens JB, Chevrolet JC. Pulmonary vascular reactivity in severe pulmonary hypertension associated with mixed connective tissue disease. Thorax 1995;50: 96-7.
9. Weir EK, Rubin LJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. The acute administration of vasodilators in primary pulmonary hypertension. Am Rev Respir Dis 1989;140:1623-30.
10. Fishman AP. The National Registry on Primary Pulmonary Hypertension. Eur Respir Res 1995;5:259-63.
11. Rich S, Brundage B. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation 1987;76:135-41.
12. Jones DK, Higenbottam TW, Wallwork J. Treatment of primary pulmonary hypertension with intravenous epoprostenol. Br Heart J 1987;57:270-8.
13. 2 supports blood flow to hypoxic alveoli in anesthetized dogs. J Appl Physiol 1984;56:1246-51.
14. Lynch JP, Myhre JG, Dantzker DR. Influence of cardiac output on intrapulmonary shunt. J Appl Physiol 1979;46: 315-21.